The Scientist

» Big Pharma and immunology

Most Recent

image: Repurposed Retroviruses

Repurposed Retroviruses

By | December 18, 2014

B cells have commandeered ancient viral sequences in the genome to transmit antigen signals.


image: Merck Buys Cubist for $8.4B

Merck Buys Cubist for $8.4B

By | December 11, 2014

Hours after the pharmaceutical giant announced the acquisition, a federal judge invalidated key patents behind the antibiotic maker’s most lucrative product.


image: Platelets Fan Inflammation

Platelets Fan Inflammation

By | December 4, 2014

The circulating blood cells bind to neutrophils, prompting inflammation-related activity in these immune cell partners.


image: Gut Microbes Trigger Malaria-Fighting Antibodies

Gut Microbes Trigger Malaria-Fighting Antibodies

By | December 4, 2014

A carbohydrate antigen found on cells of E. coli and other species prompts a potent immune response against malaria-causing parasites in mice.

1 Comment

image: All Systems Go

All Systems Go

By | December 1, 2014

Alan Aderem earned his PhD while under house arrest for protesting apartheid in South Africa. His early political involvement has guided his scientific focus, encouraging fellow systems biologists to study immunology and infectious diseases.


image: Bespoke Cell Jackets

Bespoke Cell Jackets

By | December 1, 2014

Scientists make hydrogel coats for individual cells that can be tailored to specific research questions.


image: Taking Shots at Ebola

Taking Shots at Ebola

By | November 5, 2014

With an infusion of public and private resources and accelerated regulatory processes, a handful of companies are racing to develop a vaccine to curb the Ebola epidemic.


image: Poor Little Devils

Poor Little Devils

By | November 1, 2014

See the devastating infectious cancer that may drive the Tasmanian Devil to extinction.


image: Epigenetics of Trained Innate Immunity

Epigenetics of Trained Innate Immunity

By | September 25, 2014

Documenting the epigenetic landscape of human innate immune cells reveals pathways essential for training macrophages.


image: Roche Buys Biotech for $8.3B

Roche Buys Biotech for $8.3B

By | August 27, 2014

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.


Popular Now

  1. Investigation Finds Pathologist Guilty of Systemic Misconduct
  2. Misconduct Finding Could Impact PubPeer Litigation
  3. Common STD May Have Come from Neanderthals
  4. Bacteria and Humans Have Been Swapping DNA for Millennia